Design paper for a two-site, 21-month, phase 3 double-masked RCT of nicotinamide 3 g/day plus calcium pyruvate 1 g/day vs placebo for neuroprotection in treated open-angle glaucoma; primary outcome is visual field and/or OCT progression. No results yet.
RCT
Shukla et al. Nicotinamide and Pyruvate in Open-Angle Glaucoma: A Randomized Controlled Trial on Neuroprotection-Design and Methodology